

OFFICIAL

MAY 14 2002
PATENT
6745081 GROUP 1600

AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

IN THE CLAIMS

Please amend the following claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

D¹
1. (Thrice Amended) A chaperone polypeptide having refolding activity and having an amino acid sequence selected from at least amino acid residues 230-271 but no more than residues 150-455 or 151-456 of a GroEL sequence as shown in Figure 7, wherein positions 262 and 267 are occupied by amino acid residues other than alanine and isoleucine, respectively, or a corresponding sequence of a chaperone polypeptide, said corresponding sequence sharing at least 50% homology with said amino acid sequence.

D²
13. (Twice amended) A monomeric polypeptide, having chaperone activity and incapable of multimerisation, characterised in that, in the absence of ATP, the polypeptide has a protein refolding activity of more than 50%, said refolding activity being determined by contacting the polypeptide with an inactivated protein of known specific activity prior to inactivation, and then determining the specific activity of the said protein after contact with the polypeptide, the % refolding activity being:

$$\frac{\text{specific activity of protein after contact with polypeptide} \times 100}{\text{specific activity of protein prior to inactivation}} \quad 1$$

wherein the selected amino acid sequence is selected from the group consisting of 230-271, 191-345, 191-376, 193-335 and 193-337 of GroEL, wherein positions 262 and 267 are occupied by amino acid residues other than alanine and isoleucine, respectively, or a corresponding sequence of a chaperone polypeptide, said corresponding sequence sharing at least 50% homology with said amino acid sequence.

Please add the following claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

D³
55. (New) A chaperone polypeptide having refolding activity and having an amino acid sequence selected from at least amino acid residues 230-271 but no more than residues 150-455 or 151-456 of a GroEL sequence as shown in Figure 7, wherein position 262 is occupied by leucine and/or position 267 is occupied by methionine, or a corresponding sequence of a

chaperone polypeptide, said corresponding sequence sharing at least 50% homology with said amino acid sequence.

56. (New) A monomeric polypeptide, having chaperone activity and incapable of multimerisation, characterised in that, in the absence of ATP, the polypeptide has a protein refolding activity of more than 50%, said refolding activity being determined by contacting the polypeptide with an inactivated protein of known specific activity prior to inactivation, and then determining the specific activity of the said protein after contact with the polypeptide, the % refolding activity being:

$$\frac{\text{specific activity of protein after contact with polypeptide} \times 100}{\text{specific activity of protein prior to inactivation}} \quad 1$$

wherein the selected amino acid sequence is selected from the group consisting of 230-271, 191-345, 191-376, 193-335 and 193-337 of GroEL, wherein position 262 is occupied by leucine and/or position 267 is occupied by methionine, or a corresponding sequence of a chaperone polypeptide, said corresponding sequence sharing at least 50% homology with said amino acid sequence.

Please cancel claims 51-54 without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.